Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 2;7(4):ofaa079.
doi: 10.1093/ofid/ofaa079. eCollection 2020 Apr.

Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey

Colin Swenson  1 , Nicole C Lapinel  2 , Juzar Ali  2
Affiliations

Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey

Colin Swenson et al. Open Forum Infect Dis. .

Abstract

Patients with Mycobacterium avium complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management of ALIS-associated respiratory adverse events. Most respondents experienced these events, but management through physician-guided measures (eg, bronchodilator use, oral rinses, and/or temporary dosing adjustments) resulted in symptomatic improvement.

Keywords: ALIS; MAC lung disease; amikacin; survey; tolerability.

PubMed Disclaimer

References

    1. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 2014; 11:425–34. - PMC - PubMed
    1. Bruguera-Avila N, Marin A, Garcia-Olive I, et al. Effectiveness of treatment with nebulized colistin in patients with COPD. Int J Chron Obstruct Pulmon Dis 2017; 12:2909–15. - PMC - PubMed
    1. Leuschner G, Behr J. Acute exacerbation in interstitial lung disease. Front Med (Lausanne) 2017; 4:176. - PMC - PubMed
    1. Shapiro AJ, Zariwala MA, Ferkol T, et al. ; Genetic Disorders of Mucociliary Clearance Consortium Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr Pulmonol 2016; 51:115–32. - PMC - PubMed
    1. Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2:738–49. - PubMed